SES
23.2.2021 08:52:12 CET | Business Wire | Press release
Four of the top five major cruise companies have entered into long-term strategic framework agreements, with the majority extending through 2026 and beyond, for services delivered over SES's next-generation O3b mPOWER communications system, SES announced today. These agreements will enable enhanced connectivity experiences onboard their current fleets as well as ships planned as part of their extensive new-build programmes, and result in a backlog of over EUR 220 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222006011/en/
The advanced connectivity solutions delivered by SES will elevate guest connectivity to provide an ultimate digital immersive experience, enabling more wearable technologies and unlocking more personalised services. This reflects a major trend across the cruise industry and the priorities of leading cruise companies as they prepare to resume sailing. The latest contracts with SES Networks reinforce that SES is the clear market leader within the cruise connectivity segment, having secured significant market share of the cruise companies' mega new-build ship programmes. Dating back to 2019, SES has provided over 13 Gbps – or 2/3 of the total capacity delivered to the cruise industry.
O3b mPOWER is SES's global terabit-level scalable constellation that will operate in medium earth orbit (MEO) – or 8,000km away from earth. Based on the proven success of SES's current O3b system, the new system provides an unprecedented increase in flexibility and throughput and is capable of continuously delivering multiple gigabits per second to a single ship anywhere on earth during seasonal peaks and in areas of high density. O3b mPOWER’s advanced technical features, which include a “follow-the-ship” capability, allow for maximum efficiency in delivering the highest throughput available today wherever a ship is travelling. The new O3b mPOWER system provides the ideal combination of global coverage and low-latency, high-throughput performance for the cruise market, ensuring seamless immersive wi-fi and connectivity experiences.
With satellites scheduled to launch in late 2021 and service beginning in 2022, the high-performance connectivity delivered by O3b mPOWER will help the cruise industry to:
- Leverage a highly-resilient global network to deliver an always-on fibre-like connectivity experience
- Deliver seamless and secured access to cloud-based platforms and applications for shipboard productivity, passenger communications and entertainment
- Dynamically optimise the required bandwidth and increased connectivity to any ship wherever and whenever it may be
- Deliver fastest internet speeds at sea, resulting in truly immersive guest experiences
- Achieve cruise liners’ operational efficiencies by enabling real-time condition monitoring and other connected Operational Technology (OT)
“COVID-19 has been challenging for the cruise industry. At the same time, it has also enabled major players in the industry to re-strategise on their plans for the future and focus on technology-driven innovation and how they can outdo themselves in creating the best holiday experience for passengers, and high-performance connectivity is central to those strategies. We are pleased to be co-creating these advanced solutions along with our customers and ensuring we can meet their future needs,” said JP Hemingway, CEO of SES Networks.
Follow us on:
https://twitter.com/SES_Satellites
https://www.facebook.com/SES.Satellites
https://www.youtube.com/ses
https://www.linkedin.com/company/ses/
https://www.instagram.com/ses_satellites/
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222006011/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom